Enhanced norepinephrine output during long-term desipramine treatment: A possible role for the extraneuronal monoamine transporter (SLC22A3)

John J. Mooney, Jacqueline A. Samson, John Hennen, Kathleen Pappalardo, Nancy McHale, Jonathan Alpert, Martha Koutsos, Joseph J. Schildkraut

Research output: Contribution to journalArticle

15 Scopus citations

Abstract

To study the delay (2-6 weeks) between initial administration of norepinephrine reuptake inhibitor antidepressants and onset of clinical antidepressant action, we examined the effects of desipramine treatment on urinary and plasma catecholamines and their metabolites during the initial 6 weeks of treatment in depressed patients. Catecholamines and metabolites in 24-h urine collections and 8:00 a.m. plasma samples were measured at baseline and after 1, 4, and 6 weeks of desipramine treatment. Desipramine treatment produced significant increases in urinary norepinephrine (NE) and normetanephrine (NMN) and plasma NE at Weeks 4 and 6, but not at Week 1. The ratio of urinary NE/NMN was increased at Weeks 4 and 6, suggesting a reduction in the metabolism of NE to NMN at extraneuronal sites by Weeks 4 and 6. The increases in urinary NE and NMN and plasma NE at Weeks 4 and 6 of desipramine treatment were associated with a reduction in the conversion of NE to NMN. This would be compatible with a blockade of the extraneuronal monoamine transporter (organic cation transporter 3; SLC22A3) by NMN. Inhibition of the extraneuronal monoamine transporter may be an important component in the clinical pharmacology of the norepinephrine reuptake inhibitor antidepressant drugs, such as desipramine. The ClinicalTrials.gov Identifier for this study is NCT00320632.

Original languageEnglish (US)
Pages (from-to)605-611
Number of pages7
JournalJournal of Psychiatric Research
Volume42
Issue number8
DOIs
Publication statusPublished - Jul 1 2008
Externally publishedYes

    Fingerprint

Keywords

  • Depression
  • Desipramine
  • Extraneuronal monoamine transporter
  • Norepinephrine
  • SLC22A3

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this